Home PC News LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company

LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company

Join executive leaders at the AI at the Edge & IoT Summit. Watch now!


Multi-year collaboration where LabGenius will apply its ML-driven protein engineering platform, EVATM, to the optimization of therapeutic NANOBODY® proteins

LONDON–(BUSINESS WIRE)–July 15, 2021–

LabGenius, a pioneer in the use of machine learning (ML) for protein engineering, today announced the signing of a multi-year research collaboration with Ablynx, a Sanofi company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005392/en/

LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company (Photo: Business Wire)

LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company (Photo: Business Wire)

Under the terms of the agreement, the companies will undertake a project, in the area of inflammation, that combines LabGenius’ capabilities in ML, robotic automation and synthetic biology with Ablynx’s expertise in NANOBODY® heavy chain variable domains. Over the course of the collaboration, LabGenius will use its EVATMplatform to deliver optimized NANOBODY® candidates. These molecules will then be progressed by Ablynx into further validation studies.

Dr James Field, CEO of LabGenius commented:

“We’re excited to be applying our ML-driven technology platform to support Ablynx in the optimization of novel NANOBODY® constructs. We’re hopeful that the fruits of this collaboration will ultimately have a positive impact on patients.”

Dr Edwin Moses, Chairman of LabGenius’ board and former CEO of Ablynx commented:

“Having had the pleasure of working with the Ablynx team in the past over many years, I am looking forward to this new collaboration that combines their world-leading expertise in NANOBODY® technology with LabGenius’ cutting-edge ML technology.”

Financial terms of the deal were not disclosed.

NANOBODY is a registered trademark of Ablynx N.V.

– end –

About LabGenius

LabGenius is a leading ML-driven protein engineering company. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of computer science, robotic automation and synthetic biology. Headquartered in London, UK, the LabGenius team includes experts in protein engineering, synthetic biology, software engineering, data science and robotic automation.

For more information, please visit www.labgeni.us, or connect on Twitter, Facebook, and LinkedIn.

LabGenius
Lucy Shaw
Communications Lead
[email protected] 

VentureBeat

VentureBeat’s mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact.

Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:

  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more

Become a member

Most Popular

Recent Comments